• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Beta-IFN injections in the morning may improve flu-like symptoms

September 7, 2011  

No gain with higher dose of glatiramer acetate

August 24, 2011  

Oral cladribine discontinued for MS

June 29, 2011  

MS incidence higher in African Americans

April 15, 2011  

Comorbidities common, delay MS diagnosis

April 15, 2011  

Fingolimod: disease-free rates and effect on brain atrophy

April 15, 2011  

MS patients may prefer new therapies regardless of risk

April 14, 2011  

Alemtuzumab reduces 1-year sustained disability: CAMS223 analysis

April 14, 2011  

Natalizumab discontinuation/interruption: relapse risk, poor tolerability

April 13, 2011  

3-month disability progression reduced with fingolimod

April 13, 2011  
Previous
37
38
39
40
41
Next

Browse by Topic

  • MS (444)
  • CLINICAL CASES (22)
  • EAN 2026 (2)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Ofatumumab 2026 – update on real-world effectiveness posted on September 22, 2026
  • CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS posted on September 17, 2026
  • Highlights of EAN 2026 – Part 2 posted on July 9, 2026
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions